FDA Grants Priority Review to Sotorasib for KRAS G12C NSCLC

The U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for sotorasib for patients with previously treated non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation, expediting the review process and highlighting the potential of this therapy to address a critical unmet need; this signals an important update in the potential **FDA sotorasib approval** timeline. The Priority Review designation shortens the FDA review process to a target of six months, compared to the standard ten months.

Drug Overview

Sotorasib is a small molecule kinase inhibitor and a first-in-class KRAS G12C inhibitor. It functions by selectively and irreversibly inhibiting the KRAS G12C mutant protein, locking it in an inactive GDP-bound state, thereby preventing downstream signaling through the MAPK pathway. Sotorasib received accelerated approval from the FDA in 2021 for the treatment of previously treated NSCLC harboring the KRAS G12C mutation.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for non-small cell lung cancer, with sotorasib most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Insights

Sotorasib's accelerated approval was based on data from the CodeBreaK 100 trial (NCT03600883), a Phase II trial. The primary endpoint of the trial was objective response rate (ORR). Common adverse events observed with sotorasib include diarrhea, nausea, fatigue, increased liver enzymes (transaminitis), and musculoskeletal pain.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Regulatory Context

The FDA granted Priority Review to the NDA for sotorasib, a designation for drugs that, if approved, would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. This designation expedites the FDA review process to a target of six months instead of the standard ten months. Sotorasib received accelerated approval from the FDA in 2021.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for non-small cell lung cancer pricing, access, and launch sequencing.

Market Impact

Sotorasib competes with other KRAS G12C inhibitors such as adagrasib in the oncology market. KRAS G12C mutations occur in approximately 13% of NSCLC adenocarcinomas, representing a significant patient subset. Sotorasib offers an oral targeted therapy option for previously treated KRAS G12C-mutated NSCLC patients.

IntelligenceStrategic Takeaways▾

Sotorasib receives FDA priority review for KRAS G12C non-small cell lung cancer (NSCLC), marking a pivotal step in targeted cancer treatment.

Future Outlook

The FDA's Priority Review for sotorasib may lead to further label expansions and potential combination trials.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-04.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Related profiles

• sotorasib

Related coverage

• Vanda tradipitant update: FDA re-review extends to Dec. 5, 2025
• FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
• FDA approves Merck’s Keytruda for adjuvant NSCLC treatment